Antisense Approach to Inflammatory Bowel Disease: Prospects and Challenges

Overview

Journal Drugs

Specialty Pharmacology

Date 2015 Apr 26

PMID 25911184

Citations 8

Authors

Irene Marafini

Davide Di Fusco

Emma Calabrese

Silvia Sedda

Francesco Pallone

Giovanni Monteleone

Affiliations

Soon will be listed here.

Abstract

Despite the great success of anti-tumour necrosis factor-based therapies, the treatment of Crohn's disease (CD) and ulcerative colitis (UC) still remains a challenge for clinicians, as these drugs are not effective in all patients, their efficacy may wane with time, and their use can increase the risk of adverse events and be associated with the development of new immune-mediated diseases. Therefore, new therapeutic targets are currently being investigated both in pre-clinical studies and in clinical trials. Among the technologies used to build new therapeutic compounds, the antisense oligonucleotide (ASO) approach is slowly gaining space in the field of inflammatory bowel diseases (IBDs), and three ASOs have been investigated in clinical trials. Systemic administration of alicaforsen targeting intercellular adhesion molecule-1, a protein involved in the recruitment of leukocytes to inflamed intestine, was not effective in CD, even though the same compound was of benefit when given as an enema to UC patients. DIMS0150, targeting nuclear factor (NF) κB-p65, a transcription factor that promotes pro-inflammatory responses, was very promising in pre-clinical studies and is currently being tested in clinical trials. Oral mongersen, targeting Smad7, an intracellular protein that inhibits transforming growth factor (TGF)-β1 activity, was safe and well tolerated by CD patients, and the results of a phase II clinical trial showed the efficacy of the drug in inducing clinical remission in patients with active disease. In this leading article, we review the rationale and the clinical data available regarding these three agents, and we discuss the challenge of using ASOs in IBD.

Citing Articles

Disulfiram with Cu alleviates dextran sulfate sodium-induced ulcerative colitis in mice.

Zhou W, Zhang H, Huang L, Sun C, Yue Y, Cao X Theranostics. 2023; 13(9):2879-2895.

PMID: 37284442 PMC: 10240830. DOI: 10.7150/thno.81571.

LncRNAs regulating stemness in aging.

Sousa-Franco A, Rebelo K, da Rocha S, de Jesus B Aging Cell. 2018; 18(1):e12870.

PMID: 30456884 PMC: 6351848. DOI: 10.1111/acel.12870.

Functional role and therapeutic targeting of microRNAs in inflammatory bowel disease.

Soroosh A, Koutsioumpa M, Pothoulakis C, Iliopoulos D Am J Physiol Gastrointest Liver Physiol. 2017; 314(2):G256-G262.

PMID: 29146677 PMC: 5866423. DOI: 10.1152/ajpgi.00268.2017.

Polymers in the Delivery of siRNA for the Treatment of Virus Infections.

Reynolds N, Dearnley M, Hinton T Top Curr Chem (Cham). 2017; 375(2):38.

PMID: 28324594 PMC: 7100576. DOI: 10.1007/s41061-017-0127-6.

Antisense oligonucleotides delivered to the amniotic cavity in utero modulate gene expression in the postnatal mouse.

Depreux F, Wang L, Jiang H, Jodelka F, Rosencrans R, Rigo F Nucleic Acids Res. 2016; 44(20):9519-9529.

PMID: 27683224 PMC: 5175366. DOI: 10.1093/nar/gkw867.

References

Arranz A, Reinsch C, Papadakis K, Dieckmann A, Rauchhaus U, Androulidaki A . Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes. J Control Release. 2012; 165(3):163-72. DOI: 10.1016/j.jconrel.2012.11.008. View

Lawrance I, Wu F, Leite A, Willis J, West G, Fiocchi C . A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology. 2004; 125(6):1750-61. DOI: 10.1053/j.gastro.2003.08.027. View

Murakami H, Akbar S, Matsui H, Onji M . Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance. Eur J Clin Invest. 2001; 31(4):337-43. DOI: 10.1046/j.1365-2362.2001.00796.x. View

Prakash T . An overview of sugar-modified oligonucleotides for antisense therapeutics. Chem Biodivers. 2011; 8(9):1616-41. DOI: 10.1002/cbdv.201100081. View

Vegter S, Tolley K, Wilson Waterworth T, Jones H, Jones S, Jewell D . Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis. Aliment Pharmacol Ther. 2013; 38(3):284-93. DOI: 10.1111/apt.12369. View

Murano M, Maemura K, Hirata I, Toshina K, Nishikawa T, Hamamoto N . Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol. 2000; 120(1):51-8. PMC: 1905625. DOI: 10.1046/j.1365-2249.2000.01183.x. View

Shi Y, Massague J . Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003; 113(6):685-700. DOI: 10.1016/s0092-8674(03)00432-x. View

Goto A, Arimura Y, Shinomura Y, Imai K, Hinoda Y . Antisense therapy of MAdCAM-1 for trinitrobenzenesulfonic acid-induced murine colitis. Inflamm Bowel Dis. 2006; 12(8):758-65. DOI: 10.1097/00054725-200608000-00013. View

Heldin C, Miyazono K, Ten Dijke P . TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997; 390(6659):465-71. DOI: 10.1038/37284. View

10.

Baert F, Noman M, Vermeire S, Van Assche G, D Haens G, Carbonez A . Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348(7):601-8. DOI: 10.1056/NEJMoa020888. View

11.

de Jong Y, Abadia-Molina A, Satoskar A, Clarke K, Rietdijk S, Faubion W . Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol. 2001; 2(11):1061-6. DOI: 10.1038/ni720. View

12.

Yacyshyn B, Chey W, Goff J, Salzberg B, Baerg R, Buchman A . Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut. 2002; 51(1):30-6. PMC: 1773277. DOI: 10.1136/gut.51.1.30. View

13.

Glover J, Leeds J, Mant T, Amin D, Kisner D, Zuckerman J . Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp Ther. 1997; 282(3):1173-80. View

14.

Neurath M . New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 2013; 7(1):6-19. DOI: 10.1038/mi.2013.73. View

15.

Banerjee D . Genasense (Genta Inc). Curr Opin Investig Drugs. 2001; 2(4):574-80. View

16.

Davis L, Bogue D, Ramberg J, Lipsky P . Differential utilization of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T lymphocytes. J Immunol. 1991; 147(9):2913-21. View

17.

Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T . Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology. 1998; 115(2):357-69. DOI: 10.1016/s0016-5085(98)70202-1. View

18.

Kitani A, Fuss I, Nakamura K, Schwartz O, Usui T, Strober W . Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction.... J Exp Med. 2000; 192(1):41-52. PMC: 1887715. DOI: 10.1084/jem.192.1.41. View

19.

Koller E, Vincent T, Chappell A, De S, Manoharan M, Bennett C . Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res. 2011; 39(11):4795-807. PMC: 3113586. DOI: 10.1093/nar/gkr089. View

20.

Huang Z, Gan J, Jia L, Guo G, Wang C, Zang Y . An orally administrated nucleotide-delivery vehicle targeting colonic macrophages for the treatment of inflammatory bowel disease. Biomaterials. 2015; 48:26-36. DOI: 10.1016/j.biomaterials.2015.01.013. View